Vaxcyte (PCVX) Interest Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Interest Expenses data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 20.2% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was -$4.7 million, a 252.37% decrease from a year earlier, with the FY2025 full-year figure at $645.3 million, up 44.66% from the prior year.
• Interest Expenses for Q1 2026 stood at $3.7 million, down from $130.4 million in the prior quarter.
• Over the last five years, Interest Expenses for PCVX reached as high as $363.1 million in Q1 2024 and fell as low as -$8.4 million in Q4 2024.
• Historically, Interest Expenses has averaged $106.6 million across 5 years, with a median of $78.8 million in 2022.
• On a YoY basis, Interest Expenses climbed as much as 3165.83% in 2025 and fell as far as 99.15% in 2025.
• Year by year, Interest Expenses stood at $74.1 million in 2022, then surged by 235.74% to $248.9 million in 2023, then tumbled by 103.38% to -$8.4 million in 2024, then jumped by 1650.69% to $130.4 million in 2025, then plunged by 97.16% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $3.7 million in Q1 2026, $130.4 million in Q4 2025, and $118.0 million in Q3 2025.